羅欣藥業(002793.SZ):公司新藥替戈拉生片目前用於治療反流性食管炎
格隆匯6月30日丨羅欣藥業(002793.SZ)近期在業績説明會上表示,公司新藥替戈拉生片目前用於治療反流性食管炎,另外兩個新適應症:十二指腸潰瘍已完成III期臨牀研究並於2023年初上市申請獲受理,聯合根除幽門螺桿菌感染的III期臨牀研究已完成患者入組。2023年3月1日醫保執行以來,醫院准入以及市場推廣都在穩步推進,公司將及時履行信息披露義務,敬請關注公司後續發佈的相關公吿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.